Paul
04-13-2004, 05:01 AM
A breast-cancer vaccine based on a peptide of human epidermal growth factor receptor 2 (HER2/neu) was demonstrated to be safe and effective in causing an immune response as reported on March 31 2004 at the American Association of Cancer Research (AACR) 95th Annual Meeting.
The vaccine is based on the E75 peptide which is an immunogenic cytotoxic T lymphocyte (CTL) epitope from the HER2/neu protein that is over-expressed in breast cancer. The clinical study run by the United States Army's Clinical Breast-Care Project (CBCP) has enrolled 34 node-positive women whose tumors express HER2/neu; 20 of those are controls. The cross-link below will take you to the AACR news release.
The non-military portion of the CBCP's HER-2 vaccine project is being administered by Windber Medical Center located in Somerset County Pennsylvania (www.windbercare.com). It is my understanding that Windber is currently recruiting women for its HER-2 vaccine clinical trial. To participate you must test positive for the presence of the human leucocyte antigen A2 (HLA-A2) in your blood. You can contact Maureen at 1-866-253-4703 (toll free) for more information.
The vaccine is based on the E75 peptide which is an immunogenic cytotoxic T lymphocyte (CTL) epitope from the HER2/neu protein that is over-expressed in breast cancer. The clinical study run by the United States Army's Clinical Breast-Care Project (CBCP) has enrolled 34 node-positive women whose tumors express HER2/neu; 20 of those are controls. The cross-link below will take you to the AACR news release.
The non-military portion of the CBCP's HER-2 vaccine project is being administered by Windber Medical Center located in Somerset County Pennsylvania (www.windbercare.com). It is my understanding that Windber is currently recruiting women for its HER-2 vaccine clinical trial. To participate you must test positive for the presence of the human leucocyte antigen A2 (HLA-A2) in your blood. You can contact Maureen at 1-866-253-4703 (toll free) for more information.